1. Home
  2. Knowledge Base
  3. References
  4. Developments in understanding diffuse noxious inhibitory controls: pharmacological evidence from pre-clinical research

Developments in understanding diffuse noxious inhibitory controls: pharmacological evidence from pre-clinical research

Kucharczyk MW, Valiente D, Bannister K (2021) Developments in understanding diffuse noxious inhibitory controls: pharmacological evidence from pre-clinical research. J Pain Res 14:1083-1095. doi: 10.2147/JPR.S258602

Summary: This review discusses the pharmacological manipulation interrogation strategies that have been used to examine the functionality of diffuse noxious inhibitory controls (DNIC) and descending control of nociception (DCN).

Usage: Anti-DBH-SAP is one of the drugs tested to influence DNIC expression. They reference a publication that reported that icv injection of Anti-DBH-SAP abolished DCN expression. Anti-DBH-SAP (5 μg/5 μl) was injected in the left ventricle. Lesion of the LC resulted in failure of DNIC, an effect that mimics what is observed behaviorally after chronic TBI.

See: Irvine KA et al. Loss of diffuse noxious inhibitory control after traumatic brain injury in rats: A chronic issue. Exp Neurol 333:113428, 2020.

Related Products: Anti-DBH-SAP (Cat. #IT-03)

Browse Articles

Need Support?

Can't find what you're looking for? Contact us, we're here to help!